Format

Send to

Choose Destination
Anal Chem. 2012 Jun 5;84(11):4637-46. doi: 10.1021/ac3002885. Epub 2012 May 14.

Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.

Author information

1
Centre d'Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com

Abstract

This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.

PMID:
22510259
DOI:
10.1021/ac3002885
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center